

## Prostatype Genomics AB receives SEK 11.5 million in connection with warrants of series T05

**NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.**

**On September 17, 2025, the exercise period for Prostatype Genomics AB's ("Prostatype" or "the Company") warrants of series T05 ("T05") ended. In total, the exercise of T05 amounts to approximately 98.1 percent, including activated top-down underwriting commitments, which means that the Company will receive approximately SEK 11.5 million before deduction of transaction-related costs. In order to execute the underwriting commitments, the Board of Directors of Prostatype Genomics has resolved on a directed issue of shares to the underwriters ("the Directed Issue").**

In May/June 2025, Prostatype Genomics carried out a fully subscribed rights issue of units. Through the rights issue and the directed issue to the underwriters in the rights issue combined, a total of 22,623,789 T05 were issued. Each T05 entitled to subscription of one new share in Prostatype Genomics to an exercise price of SEK 0.52 during the exercise period which took place from 3 September 2025 until and including 17 September 2025.

In total, 18,795,488 T05 were exercised for subscription of new shares, corresponding to approximately SEK 9.8 million, meaning an exercise rate of approximately 83.1 percent. The top-down underwriting commitments will thus be activated in full, with approximately SEK 1.8 million, corresponding to 15 percent of the total number of T05. Thus, in total the T05 were exercised to 98.1 percent, meaning that Prostatype Genomics will receive approximately SEK 11.5 million before transaction related costs.

Through the exercise of T05 and the Directed Issue, the number of shares in Prostatype Genomics will increase by 22,189,056 shares to a total of 59,189,321 shares and the share capital will increase by a total of SEK 2,218,905.60 to SEK 5,918,932.10. The total dilution amounts to approximately 37.5 percent of the capital and votes.

Conversion from interim shares to ordinary shares is expected to take place around 2 October 2025, and the new shares are expected to be visible in subscribers' custody accounts approximately two banking days thereafter.

*"We are very pleased with the interest in the warrant exercise and the confidence shown in Prostatype Genomics and our future plans by the warrant holders. The successful outcome provides us with additional runway to execute our strategy and the initiatives ahead. With this capital in place, we can continue to create long-term value for our shareholders", says Fredrik Rickman, CEO of Prostatype Genomics.*

**The Directed Issue**

In accordance with what was communicated by the Company on 3 September 2025, underwriting commitments of approximately SEK 1.8 million were entered into to secure part of the subscription of the T05. As the exercise rate amounted to approximately 83.1 percent, the top-down underwriting commitments entered into and communicated by the Company on 3 September 2025 will be executed with approximately SEK 1.8 million, corresponding to 15 percent of the total number of T05.

The Board of Directors has therefore today, based on the authorisation granted by the annual general meeting on 15 May 2025, resolved on the Directed Issue of 3,393,568 shares to the two underwriters Tony Chouha and Ghanem Chouha (1 696 784 shares to each of the two underwriters). The subscription price in the Directed Issue is SEK 0.52 per share, which corresponds to the exercise price for T05.

The Company wished to ensure in advance that it receives certain proceeds from the exercise of T05 and therefore entered into underwritings commitments with the investors participating in the Directed Issue. The size of the Directed Issue is dependent on the warrant holders' use of T05. Warrant holders were free to use T05 and thereby limit the size of the Directed Issue. The Company further assesses that a rights issue under the current volatile market conditions would entail higher costs related to any underwriting commitments. In light of this, the Board of Directors' overall assessment is that the reasons for securing the exercise of T05 and the completion of the Directed Issue with deviation from the shareholders' preferential rights clearly and with sufficient strength outweigh the reasons that justify the main rule that new issues shall be carried out with the shareholders' preferential rights.

The subscription price in the Directed Issue has been determined based on negotiations among the underwriters and the Company, in consultation with a financial adviser and through an analysis of several market factors. Therefore, the Board of Directors of the Company considers that the subscription price has been determined on market terms and correctly reflects current market conditions and demand. Thereto, the subscription price in the Directed Issue corresponds to the exercise price for T05.

The underwriters have, according to the underwriting agreements, a right to receive a compensation of 15 percent in the form of cash or 18 percent in the form of shares, for their respective top underwriting commitments. Should the underwriters decide to receive the compensation in shares, the Board of Directors will resolve on an additional directed issue of shares, which in such case will be communicated through a separate press release.

**Advisors**

Navia Corporate Finance AB and Gemstone Capital ApS are financial advisors in connection with the warrant exercise. Advokatfirman Lindahl is the legal advisor. Nordic Issuing AB is the issuing agent.

**For more information about the transaction, please contact:**

Navia Corporate Finance AB

E-mail: [info@naviacf.se](mailto:info@naviacf.se)

Website: [www.naviacorporatefinance.com](http://www.naviacorporatefinance.com)

or

Gemstone Capital ApS  
E-mail: [info@gemstonecapital.com](mailto:info@gemstonecapital.com)  
Website: [www.gemstonecapital.com](http://www.gemstonecapital.com)

**For more information about the Company, please contact:**

Fredrik Rickman, CEO Prostatype Genomics AB  
Telephone: +46 (0)73 049 77 01  
E-mail: [fredrik.rickman@prostatypegenomics.com](mailto:fredrik.rickman@prostatypegenomics.com)

**Certified Adviser**

Tapper Partners AB  
Telephone: +46 (0)70 44 010 98  
E-mail: [ca@tapperpartners.se](mailto:ca@tapperpartners.se)

**About Prostatype Genomics**

Prostatype® is a genetic test available to patients and treating urologists as a complementary decision-making tool when considering treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

**Important information**

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Prostatype Genomics. No action has been taken, and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics takes place solely through the prospectus that Prostatype Genomics has published in May 2025.

The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons

may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.

**Forward-looking Statements**

This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", "should" "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements.

Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Markets' regulations for issuers.

*This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-09-18 19:00 CEST.*